Patents by Inventor Penglie Zhang

Penglie Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors
    Patent number: 12018016
    Abstract: Compounds of formula (A) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: June 25, 2024
    Assignee: AMGEN INC.
    Inventors: Penglie Zhang, Daniel R. Marshall, Howard S. Roth, Aubrie Harland, Ju Yang, Christopher W. Lange, Rebecca M. Lui, Antoni Krasinski
  • Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
    Patent number: 12011439
    Abstract: The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2022
    Date of Patent: June 18, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Shijie Li, Venkat Reddy Mali, Rajinder Singh, Ju Yang, Penglie Zhang
  • Aryl sulfonyl compounds as CCR6 inhibitors
    Patent number: 12012403
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: June 18, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Penglie Zhang, Daniel R. Marshall, Howard S. Roth, Aubrie Harland
  • HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES
    Publication number: 20240132495
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula I including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: November 29, 2023
    Publication date: April 25, 2024
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
  • METHODS OF TREATING CANCER USING HETEROARYL-BIPHENYL AMIDE DERIVATIVES
    Publication number: 20240115682
    Abstract: Provided herein are methods of treating certain cancers comprising administering to the subject in need there of an effective amount of a compound of Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Ra, and Rb are as defined herein.
    Type: Application
    Filed: November 15, 2023
    Publication date: April 11, 2024
    Inventors: Shijie LI, Marta VILALTA-COLOMER, Yibin ZENG, Penglie ZHANG
  • Inhibitors of CXCR2
    Patent number: 11945805
    Abstract: Compounds are provided as inhibitors of CXCR2, having the structure:
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: April 2, 2024
    Assignee: CHEMOCENTRYX, INC
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Viengkham Malathong, Jeffrey McMahon, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang, Venkat Mali
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES
    Publication number: 20240100041
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
    Type: Application
    Filed: December 6, 2023
    Publication date: March 28, 2024
    Applicant: CHEMOCENTRYX, INC.
    Inventors: James CAMPBELL, Israel CHARO, Thomas SCHALL, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
  • Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies
    Patent number: 11883391
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 30, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: James Campbell, Israel Charo, Thomas Schall, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Indanes as PD-L1 inhibitors
    Patent number: 11872217
    Abstract: Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a?, R2b?, R2c?, R3?, R4?, R5?, R6a?, R6b?, Y, Y?, and the subscripts m and n are as defined herein.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: January 16, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Viengkham Malathong, Venkat Reddy Mali, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Ju Yang, Penglie Zhang
  • Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
    Patent number: 11866429
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: January 9, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
  • Processes and intermediates in the preparation of C5aR antagonists
    Patent number: 11845729
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: December 19, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • CXCR7 antagonists
    Patent number: 11834452
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: December 5, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • CCR4 ANTAGONISTS
    Publication number: 20230382894
    Abstract: Compounds are provided having formula (I): wherein the groups/letters R1a, R1b, m, R2, R3, R4, X, Y, A, B, n, q, L and Q, have the meanings provided herein. The compounds are useful as CCR4 antagonists and are useful in treated diseases and conditions modulated by CCR4 activity.
    Type: Application
    Filed: April 18, 2023
    Publication date: November 30, 2023
    Inventors: Pingchen FAN, Rebecca M. LUI, Ryan J. SCAMP, Ju YANG, Yu WANG, Yibin ZENG, Penglie ZHANG
  • FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
    Publication number: 20230381167
    Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.
    Type: Application
    Filed: April 24, 2023
    Publication date: November 30, 2023
    Inventors: Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Antoni KRASINSKI
  • Modulators of chemokine receptors
    Patent number: 11820759
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: November 21, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Antoni Krasinski, Manmohan Reddy Leleti, Venkat Mali, Jeffrey McMahon, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • Deuterated compounds as immunomodulators
    Patent number: 11807609
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: November 7, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Rebecca M. Lui, Venkat Reddy Mali, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • CXCR6 SULFONAMIDE COMPOUNDS
    Publication number: 20230339851
    Abstract: Provided are sulfonamide compounds having formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, R4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.
    Type: Application
    Filed: March 20, 2023
    Publication date: October 26, 2023
    Inventors: Hiufung CHU, Pingchen FAN, Yandong LI, Viengkham MALATHONG, Jay POWERS, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Immunomodulator compounds
    Patent number: 11793771
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 13, 2022
    Date of Patent: October 24, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Christopher Lange, Viengkham Malathong, Darren J. McMurtrie, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
  • HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES
    Publication number: 20230322731
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 12, 2023
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
  • 6-5 fused rings as C5a inhibitors
    Patent number: 11773091
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: October 3, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang